<p>180 Wealth Advisors LLC 在第一季度增持了 MannKind Co.（NASDAQ:MNKD - Free Report）的股份，增幅为 12.6%，根据其最新提交给证券交易委员会的 13F 表格。该公司在本季度购入了额外的 216,880 股，持有这家生物制药公司的 1,942,210 股股票。MannKind 占 180 Wealth Advisors LLC 投资组合的约 1.6%，是其第 6 大持仓。根据最新提交给证券交易委员会的文件，180 Wealth Advisors LLC 持有的 MannKind 股份价值 8,798,000 美元，占其投资组合的 0.72%。</p>
<p>许多其他机构投资者和对冲基金最近也买入和卖出了该公司的股票。Parkman Healthcare Partners LLC 在第 4 季度增持了 MannKind 的持股比例 20.8%。Parkman Healthcare Partners LLC 现在拥有 2,498,624 股这家生物制药公司的股票，价值 9,095,000 美元，比上一季度增持了 429,677 股。Charles Schwab Investment Management Inc.在第 4 季度增持了 MannKind 的持股比例 1.5%。Charles Schwab Investment Management Inc.现在拥有 2,066,844 股这家生物制药公司的股票，价值 7,523,000 美元，比上一季度增持了 30,433 股。Invesco Ltd.在第 3 季度增持了 MannKind 的持股比例 1.6%。Invesco Ltd.现在拥有 1,621,765 股这家生物制药公司的股票，价值 6,698,000 美元，比上一季度增持了 25,319 股。Schonfeld Strategic Advisors LLC 在第 3 季度增持了 MannKind 的持股比例 10.1%。Schonfeld Strategic Advisors LLC 现在拥有 973,200 股这家生物制药公司的股票，价值 4,019,000 美元，比上一季度增持了 89,005 股。最后，Connor Clark &amp; Lunn Investment Management Ltd.在第 3 季度增持了 MannKind 的持股比例 77.4%。Connor Clark &amp; Lunn Investment Management Ltd.现在拥有 740,078 股这家生物制药公司的股票，价值 3,057,000 美元，比上一季度增持了 322,791 股。该股的 49.55% 由机构投资者和对冲基金持有。</p>
<h2>内部人士的买卖行为</h2>
<p>据相关消息，执行副总裁 David Thomson 于 5 月 21 日星期二进行了一笔交易，卖出了 23,537 股股票。该股票以每股平均价格 4.66 美元出售，总价值为 109,682.42 美元。交易完成后，该执行副总裁在公司中持有 873,616 股股票，价值 4,071,050.56 美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接处查看。目前有 3.00% 的股份由公司内部人士持有。</p>
<h2>分析师设定新的价格目标</h2>
<p>MNKD 最近成为多份分析师报告的主题。Rodman &amp; Renshaw 在 6 月 13 日星期四的一份报告中开始对 MannKind 进行覆盖。他们给予该股票一个&#34;买入&#34;评级，并设定了 8.00 美元的股价目标。Cantor Fitzgerald 在 5 月 9 日星期四重申了对 MannKind 的&#34;超重&#34;评级，并设定了 6.50 美元的股价目标。一位研究分析师给予该股票持有评级，另外四位分析师给予该公司买入评级。根据 MarketBeat 的数据，该股票的共识评级为&#34;中度买入&#34;，共识价格目标为 8.00 美元。</p>
<p><strong>查看我们对 MNKD 的最新分析</strong></p>
<h2>MannKind 股价下跌 1.5%</h2>
<p>MNKD 股票在周五交易时下跌了 0.08 美元，报 5.21 美元。该公司的股票在交易时段内交易量为 373,131 股，相比平均交易量 2,719,187 股。该公司的市值为 14.2 亿美元，市盈率为 176.39，贝塔系数为 1.27。MannKind Co.的 52 周最低价为 3.17 美元，最高价为 5.75 美元。该公司的 50 天移动平均价格为 4.61 美元，200 天移动平均价格为 4.17 美元。</p>
<p>MannKind（NASDAQ:MNKD - Get Free Report）于 5 月 8 日星期三发布了其财报。这家生物制药公司在本季度每股盈利为 0.05 美元，超过分析师预期的 0.03 美元。该公司本季度的营收为 6626 万美元，超过预期的 6055 万美元。MannKind 的净资产回报率为-3.35%，净利润率为 3.78%。该公司本季度的营收同比增长了 63.1%。在去年同期的同一季度，该公司每股亏损为（0.04）美元。作为一个整体，分析师预计 MannKind Co.在本财年将实现 0.1 美元的每股盈利。</p>
<h2>MannKind 简介（免费报告）</h2>
<p>MannKind Corporation 是一家生物制药公司，专注于开发和销售用于美国内分泌和孤儿肺部疾病的吸入治疗产品。公司提供 Afrezza，一种用于改善成年糖尿病患者血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送装置，为成年人提供持续皮下注射胰岛素。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票，比 MannKind 更好</li>
<li>股市假期 2022-2025 年 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>Salesforce 股票：会议总结，人工智能重点和预测</li>
<li>突破性股票：它们是什么以及如何识别它们</li>
<li>CAVA 是否过度扩张？对这只高飞股票的更近一步了解</li>
<li>消费类必需品股票，解释</li>
<li>Nike 股价在分析师下调目标后跌至低谷</li>
</ul>
<p><strong>想看看其他对冲基金持有 MNKD 的情况？</strong> 访问 HoldingsChannel.com 获取 MannKind Co.（NASDAQ:MNKD - Free Report）的最新 13F 提交和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 人工智能真正的下一步发展方向（来自 InvestorPlace）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2"/></p>
<h2>现在是否值得投资曼恩凯德生物医疗？</h2>
<p>在考虑曼恩凯德生物医疗之前，您需要听到这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而曼恩凯德生物医疗不在这个列表上。</p>
<p>虽然曼恩凯德生物医疗目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

曼恩凯德生物医疗

<p>180 Wealth Advisors LLC 在第一季度增加了对 MannKind Co. (NASDAQ: MNKD) 的持股比例，根据其最新提交给证券交易委员会的文件，持股比例增加了 12.6%。该公司现在拥有该生物制药公司的 1,942,210 股股份，使其成为他们的第 6 大持仓。MannKind 的股价目前为$5.21</p>

<p>180 Wealth Advisors LLC increased its stake in MannKind Co. (NASDAQ:MNKD - Free Report) by 12.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 1,942,210 shares of the biopharmaceutical company's stock after purchasing an additional 216,880 shares during the quarter. MannKind comprises about 1.6% of 180 Wealth Advisors LLC's portfolio, making the stock its 6th biggest holding. 180 Wealth Advisors LLC owned 0.72% of MannKind worth $8,798,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>180 Wealth Advisors LLC 在第一季度增持了 MannKind Co.（NASDAQ:MNKD - Free Report）的股份，增幅为 12.6%，根据其最新提交给证券交易委员会的 13F 表格。该公司在本季度购入了额外的 216,880 股，持有这家生物制药公司的 1,942,210 股股票。MannKind 占 180 Wealth Advisors LLC 投资组合的约 1.6%，是其第 6 大持仓。根据最新提交给证券交易委员会的文件，180 Wealth Advisors LLC 持有的 MannKind 股份价值 8,798,000 美元，占其投资组合的 0.72%。</p>
</div><p>A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Parkman Healthcare Partners LLC lifted its holdings in MannKind by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 2,498,624 shares of the biopharmaceutical company's stock valued at $9,095,000 after acquiring an additional 429,677 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in MannKind by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,066,844 shares of the biopharmaceutical company's stock valued at $7,523,000 after acquiring an additional 30,433 shares during the last quarter. Invesco Ltd. lifted its holdings in MannKind by 1.6% in the 3rd quarter. Invesco Ltd. now owns 1,621,765 shares of the biopharmaceutical company's stock valued at $6,698,000 after acquiring an additional 25,319 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in MannKind by 10.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 973,200 shares of the biopharmaceutical company's stock worth $4,019,000 after buying an additional 89,005 shares during the period. Finally, Connor Clark &amp; Lunn Investment Management Ltd. raised its holdings in MannKind by 77.4% during the 3rd quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 740,078 shares of the biopharmaceutical company's stock worth $3,057,000 after buying an additional 322,791 shares during the period. 49.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>许多其他机构投资者和对冲基金最近也买入和卖出了该公司的股票。Parkman Healthcare Partners LLC 在第 4 季度增持了 MannKind 的持股比例 20.8%。Parkman Healthcare Partners LLC 现在拥有 2,498,624 股这家生物制药公司的股票，价值 9,095,000 美元，比上一季度增持了 429,677 股。Charles Schwab Investment Management Inc.在第 4 季度增持了 MannKind 的持股比例 1.5%。Charles Schwab Investment Management Inc.现在拥有 2,066,844 股这家生物制药公司的股票，价值 7,523,000 美元，比上一季度增持了 30,433 股。Invesco Ltd.在第 3 季度增持了 MannKind 的持股比例 1.6%。Invesco Ltd.现在拥有 1,621,765 股这家生物制药公司的股票，价值 6,698,000 美元，比上一季度增持了 25,319 股。Schonfeld Strategic Advisors LLC 在第 3 季度增持了 MannKind 的持股比例 10.1%。Schonfeld Strategic Advisors LLC 现在拥有 973,200 股这家生物制药公司的股票，价值 4,019,000 美元，比上一季度增持了 89,005 股。最后，Connor Clark &amp; Lunn Investment Management Ltd.在第 3 季度增持了 MannKind 的持股比例 77.4%。Connor Clark &amp; Lunn Investment Management Ltd.现在拥有 740,078 股这家生物制药公司的股票，价值 3,057,000 美元，比上一季度增持了 322,791 股。该股的 49.55% 由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士的买卖行为</h2>
</div><p>In related news, EVP David Thomson sold 23,537 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $4.66, for a total value of $109,682.42. Following the transaction, the executive vice president now owns 873,616 shares in the company, valued at $4,071,050.56. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. 3.00% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>据相关消息，执行副总裁 David Thomson 于 5 月 21 日星期二进行了一笔交易，卖出了 23,537 股股票。该股票以每股平均价格 4.66 美元出售，总价值为 109,682.42 美元。交易完成后，该执行副总裁在公司中持有 873,616 股股票，价值 4,071,050.56 美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接处查看。目前有 3.00% 的股份由公司内部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>MNKD has been the topic of several recent analyst reports. Rodman &amp; Renshaw initiated coverage on MannKind in a report on Thursday, June 13th. They set a &#34;buy&#34; rating and a $8.00 price objective on the stock. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $6.50 price objective on shares of MannKind in a report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.00.</p>
<div class="lb-trans"><p>MNKD 最近成为多份分析师报告的主题。Rodman &amp; Renshaw 在 6 月 13 日星期四的一份报告中开始对 MannKind 进行覆盖。他们给予该股票一个&#34;买入&#34;评级，并设定了 8.00 美元的股价目标。Cantor Fitzgerald 在 5 月 9 日星期四重申了对 MannKind 的&#34;超重&#34;评级，并设定了 6.50 美元的股价目标。一位研究分析师给予该股票持有评级，另外四位分析师给予该公司买入评级。根据 MarketBeat 的数据，该股票的共识评级为&#34;中度买入&#34;，共识价格目标为 8.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on MNKD</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MNKD 的最新分析</strong></p>
</div><h2>MannKind Stock Down 1.5 %</h2>
<div class="lb-trans"><h2>MannKind 股价下跌 1.5%</h2>
</div><p>Shares of MNKD traded down $0.08 during trading hours on Friday, reaching $5.21. The company's stock had a trading volume of 373,131 shares, compared to its average volume of 2,719,187. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 176.39 and a beta of 1.27. MannKind Co. has a 1-year low of $3.17 and a 1-year high of $5.75. The company has a 50 day moving average of $4.61 and a two-hundred day moving average of $4.17.</p>
<div class="lb-trans"><p>MNKD 股票在周五交易时下跌了 0.08 美元，报 5.21 美元。该公司的股票在交易时段内交易量为 373,131 股，相比平均交易量 2,719,187 股。该公司的市值为 14.2 亿美元，市盈率为 176.39，贝塔系数为 1.27。MannKind Co.的 52 周最低价为 3.17 美元，最高价为 5.75 美元。该公司的 50 天移动平均价格为 4.61 美元，200 天移动平均价格为 4.17 美元。</p>
</div><p>MannKind (NASDAQ:MNKD - Get Free Report) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.02. The company had revenue of $66.26 million for the quarter, compared to the consensus estimate of $60.55 million. MannKind had a negative return on equity of 3.35% and a net margin of 3.78%. The firm's quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. As a group, analysts forecast that MannKind Co. will post 0.1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MannKind（NASDAQ:MNKD - Get Free Report）于 5 月 8 日星期三发布了其财报。这家生物制药公司在本季度每股盈利为 0.05 美元，超过分析师预期的 0.03 美元。该公司本季度的营收为 6626 万美元，超过预期的 6055 万美元。MannKind 的净资产回报率为-3.35%，净利润率为 3.78%。该公司本季度的营收同比增长了 63.1%。在去年同期的同一季度，该公司每股亏损为（0.04）美元。作为一个整体，分析师预计 MannKind Co.在本财年将实现 0.1 美元的每股盈利。</p>
</div><h2>MannKind Profile (Free Report)</h2>
<div class="lb-trans"><h2>MannKind 简介（免费报告）</h2>
</div><p>MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.</p>
<div class="lb-trans"><p>MannKind Corporation 是一家生物制药公司，专注于开发和销售用于美国内分泌和孤儿肺部疾病的吸入治疗产品。公司提供 Afrezza，一种用于改善成年糖尿病患者血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送装置，为成年人提供持续皮下注射胰岛素。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than MannKind</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Salesforce Stock: Meeting Recap, AI Focus, and Forecast</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Is CAVA Overextended? A Closer Look at This High-Flying Stock</li>
<li>Consumer Staples Stocks, Explained</li>
<li>Nike Stock Falls to Bargain Basement After Analysts Slash Targets</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票，比 MannKind 更好</li>
<li>股市假期 2022-2025 年 - 纽约证券交易所和纳斯达克将关闭的时间</li>
<li>Salesforce 股票：会议总结，人工智能重点和预测</li>
<li>突破性股票：它们是什么以及如何识别它们</li>
<li>CAVA 是否过度扩张？对这只高飞股票的更近一步了解</li>
<li>消费类必需品股票，解释</li>
<li>Nike 股价在分析师下调目标后跌至低谷</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding MNKD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MannKind Co. (NASDAQ:MNKD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 MNKD 的情况？</strong> 访问 HoldingsChannel.com 获取 MannKind Co.（NASDAQ:MNKD - Free Report）的最新 13F 提交和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MNKD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 的编辑团队审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Where AI is REALLY Going Next (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 人工智能真正的下一步发展方向（来自 InvestorPlace）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8506&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in MannKind right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资曼恩凯德生物医疗？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑曼恩凯德生物医疗之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而曼恩凯德生物医疗不在这个列表上。</p>
</div><p>While MannKind currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然曼恩凯德生物医疗目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

曼恩凯德生物医疗公司（NASDAQ:MNKD）的股份被 180 财富顾问公司收购